Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $53.1 million.

  • Caribou Biosciences' Total Liabilities fell 1582.74% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 1582.74%. This contributed to the annual value of $60.4 million for FY2024, which is 540.06% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Total Liabilities is $53.1 million, which was down 1582.74% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Total Liabilities ranged from a high of $80.2 million in Q2 2023 and a low of $35.7 million during Q1 2021
  • For the 5-year period, Caribou Biosciences' Total Liabilities averaged around $62.4 million, with its median value being $62.5 million (2024).
  • In the last 5 years, Caribou Biosciences' Total Liabilities surged by 142627.56% in 2021 and then tumbled by 2209.16% in 2024.
  • Caribou Biosciences' Total Liabilities (Quarter) stood at $54.5 million in 2021, then soared by 33.67% to $72.9 million in 2022, then dropped by 12.46% to $63.8 million in 2023, then decreased by 5.4% to $60.4 million in 2024, then fell by 11.97% to $53.1 million in 2025.
  • Its Total Liabilities was $53.1 million in Q3 2025, compared to $54.8 million in Q2 2025 and $56.4 million in Q1 2025.